Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (PYXS) is a clinical-stage biopharmaceutical company pioneering antibody-drug conjugates (ADCs) targeting components of the tumor microenvironment to address challenging cancers. This page provides investors and researchers with a comprehensive repository of official announcements, clinical trial updates, and strategic developments.
Access timely updates on PYX-201 progress, partnership agreements, and regulatory milestones. Our curated collection includes earnings reports, preclinical data disclosures, and management commentary – all essential for evaluating the company’s position in oncology innovation.
Key content categories include ADC platform advancements, clinical trial phase transitions, and scientific collaborations. Users will find verified information on therapeutic mechanisms targeting extracellular matrix proteins like EDB+FN, a focus area distinguishing Pyxis in immuno-oncology.
Bookmark this page for streamlined access to material events affecting Pyxis Oncology’s trajectory. Check regularly for new developments in their pipeline programs and evidence-based analysis of therapeutic candidates.
Pyxis Oncology (NASDAQ: PYXS) reported 3Q25 results and a program update on Nov 3, 2025. The company ended 3Q25 with $77.7 million in cash, cash equivalents and short-term investments and expects runway into the second half of 2026. Pyxis expects to report preliminary Phase 1 clinical data for micvotabart pelidotin (MICVO) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in 4Q25, covering monotherapy dose expansion (2L/3L arms) and combination dose escalation with KEYTRUDA under a Clinical Trial Collaboration Agreement with Merck.
Translational posters at ESMO and AACR-NCI-EORTC showed ctDNA reductions in the majority of 37 clinical samples and signals at the 5.4 mg/kg dose, supporting continued development.
Pyxis Oncology (NASDAQ: PYXS) will present translational data for micvotabart pelidotin (MICVO), a first-in-concept extracellular-cleaving ADC targeting EDB+FN, at ESMO 2025 (Oct 17-21) and AACR-NCI-EORTC Boston (Oct 22-26).
Key findings highlight a three-pronged mechanism—direct tumor cell killing, bystander killing, and immunogenic cell death—and report tumor microenvironment remodeling and immune activation. Observations included reductions in circulating tumor DNA tumor fraction in the vast majority of 37 clinical samples tested, with notable ctDNA TF decreases in HNSCC at the 5.4 mg/kg dose. Digital pathology features of stromal architecture may correlate with MICVO sensitivity.
Pyxis Oncology (Nasdaq: PYXS) appointed Alex Kane as Senior Vice President, Investor Relations & Capital Markets, effective October 9, 2025. Kane joins with 20 years of life‑science investor relations and equity capital markets experience, most recently at Guggenheim Securities.
His background includes investor relations and communications roles at Praxis Precision Medicines and PTC Therapeutics and prior leadership at W2O Group, Nasdaq, and Thomson Reuters. Kane holds an MBA in Finance and Entrepreneurship from NYU Stern and a BA in International Political Economy from Colorado College. Management highlights cite his experience with IPOs, secondary offerings, and investor engagement as relevant to advancing Pyxis Oncology’s clinical programs and upcoming milestones.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on antibody-drug conjugate therapeutics, has granted stock options to seven new employees under its 2022 Inducement Plan. The grants total 382,518 shares, with 261,268 shares vesting over four years and 121,250 shares vesting on December 31, 2025.
The stock options have a ten-year term and an exercise price of $2.22 per share, matching Pyxis Oncology's closing stock price on September 30, 2025. These grants were made as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing antibody-drug conjugate therapeutics, has announced its participation in three upcoming conferences in September 2025.
The company's CEO, Dr. Lara S. Sullivan, will participate in fireside chats at the 2025 Cantor Global Healthcare Conference on September 3 and the H.C. Wainwright Global Investment Conference on September 8. Additionally, Pyxis will present at the 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit on September 9.
Webcasts for the investor conference presentations will be available on the company's investor relations website.
Pyxis Oncology (Nasdaq: PYXS) reported Q2 2025 financial results and provided updates on its clinical programs. The company's lead antibody-drug conjugate (ADC) candidate, micvotabart pelidotin (MICVO), is advancing in clinical trials with preliminary data expected in H2 2025 and H1 2026.
Key financial highlights include $90.4 million in cash and investments, providing runway into H2 2026. Q2 revenues were $2.8 million from a milestone payment from Simcere, with a net loss of $18.4 million ($0.30 per share). R&D expenses increased to $17.1 million, while G&A expenses decreased to $5.4 million.
The company is progressing with two key clinical trials: a Phase 1 monotherapy study for head and neck cancer and a Phase 1/2 combination study with KEYTRUDA®, both showing promising potential in treating advanced solid tumors.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation antibody-drug conjugate therapeutics, has announced the granting of inducement stock options to four new employees. The company's Compensation Committee approved options to purchase 246,238 shares of common stock under the 2022 Inducement Plan.
The stock options are structured in two tranches: 181,238 options vest over four years with 25% vesting after one year and the remainder monthly over 36 months, while 65,000 options vest fully on December 31, 2025. All options have a ten-year term and an exercise price of $1.10 per share, matching Pyxis Oncology's closing stock price on June 30, 2025.
Pyxis Oncology (NASDAQ: PYXS), a clinical-stage company focused on developing next-generation ADC therapeutics for difficult-to-treat cancers, has announced its participation in two upcoming investor conferences. The company's President, CEO, and CMO, Dr. Lara S. Sullivan, will engage in fireside chats at:
- The 2025 RBC Capital Markets Global Healthcare Conference in New York on May 21 at 2:05 p.m. ET
- The Jefferies Global Healthcare Conference in New York on June 5 at 4:55 p.m. ET
Investors can access live webcasts and replays of both presentations through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website.
Pyxis Oncology (NASDAQ: PYXS) presented promising preclinical results for micvotabart pelidotin (MICVO), their first-in-concept antibody-drug conjugate targeting Extradomain-B Fibronectin. The data, presented at AACR 2025, demonstrated:
- 45% of PDX models showed strong to very strong tumor growth inhibition
- Complete responses were observed across multiple tumor indications
- The drug was well-tolerated at 3mg/kg dosing
- Combination therapy with anti-PD-1 achieved 91% tumor growth inhibition with complete response in 9/15 animals
MICVO's three-pronged mechanism of action includes direct tumor killing, bystander effect, and immunogenic cell death. The drug is currently in Phase 1 trials as both monotherapy and in combination with KEYTRUDA for advanced solid tumors.
FAQ
What is the current stock price of Pyxis Oncology (PYXS)?
What is the market cap of Pyxis Oncology (PYXS)?
